05:01:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2023-09-11 08:45:00

The exercise period for warrants series TO 3 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in April 2023 (the "Rights Issue") begins today, 11 September 2023.

Terms for warrants series TO 3 in brief:
 

  • The exercise price is SEK 0.11 per share.
  • The exercise period runs from 11 - 29 September 2023.
  • Each warrant entitles the holder to subscribe for 1 share. Upon exercise of all 622,348,940 outstanding warrants, 622,348,940 shares will be issued.
  • If the warrants are fully exercised, the Company will receive approximately MSEK 68.5 before issue costs.
  • Upon full exercise of all warrants, the number of shares in Qlife will increase with 622,348,940 to 1,267,784,439 shares, and the share capital will increase with SEK 49,787,915.20 to SEK 101,422,755.12.
  • The outcome is planned to be announced on 3 October 2023.
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 3. The exercise period of the warrants will run from 11 - 29 September 2023. One (1) warrant entitles the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.11.

In the event of full exercise of all warrants, the Company will receive approximately MSEK 68.5 before issue costs. In order for the warrants not to expire and lose their value, they must be actively sold by 27 September 2023 at the latest, or be exercised no later than 29 September 2023.

Note that warrants that have not been actively sold by 27 September 2023 at the latest, or been exercised no later than 29 September 2023, will expire and lose their value.

Exercise of warrants series TO 3
 

Trustee-registered warrants

If the warrant holder holds warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercise of the warrants.

Directly registered warrants (securities account)

Directly registered warrant holders can order an application form via info@aqurat.seor by phone on +46 8-684 05 800. Payment is made in accordance with the instructions in the application form. Both the application form and payment must be submitted to Aqurat Fondkommission AB by 15:00 CEST on 29 September 2023 at the latest.

The information was submitted for publication, through the agency of the contact person set out below, on 2023-09-11 08:45 CET.